Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial
Intensive Blutdruckkontrolle zur Prävention majorer kardiovaskulärer Ereignisse bei Schlaganfallpatient:innen: Begründung und Design der OPTIMAL-STROKE-Studie
European Stroke Journal · 05.10.2026 · 11 (10)
DOI: 10.1093/esj/aakag118 ↗Auf einen Blick
OPTIMAL-STROKE prüft bei Patient:innen mit ischämischem Schlaganfall oder TIA, ob ein SBP-Ziel < 120 mmHg majoren kardiovaskulären Ereignissen besser vorbeugt als < 140 mmHg.
Fragestellung
Reduziert ein intensives systolisches Blutdruckziel (< 120 mmHg) bei Patient:innen mit ischämischem Schlaganfall oder TIA majoren kardiovaskulären Ereignissen im Vergleich zu < 140 mmHg?
Methode
Multizentrische, randomisierte, kontrollierte, offene klinische Studie mit verblindeter, unabhängiger Endpunktbewertung und Intention-to-treat-Analyse; 1:1-Randomisierung.
Ergebnisse
Geplant sind 4.368 Patient:innen und 495 primäre Endpunktereignisse. Primärer Endpunkt ist das erste Auftreten majorer kardiovaskulärer Ereignisse.
Schlussfolgerung der Autor:innen
OPTIMAL-STROKE wird laut Autor:innen die erste ausreichend gepowerte Studie zur intensiven Blutdruckkontrolle zur Prävention majorer kardiovaskulärer Ereignisse bei Patient:innen mit IS oder TIA sein.
Kernaussagen
- SBP-Ziel < 120 mmHg vs. < 140 mmHg
- Primärer Endpunkt: majorer kardiovaskulärer Composite-Endpunkt
- Geplant: 4.368 Patient:innen, 495 primäre Ereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift European Stroke Journal, online erschienen am 06.10.2026. Verfasst von Gisele S Silva und 39 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701, Morumbi, São Paulo, SP CEP 05652-900, Brazil. Hauptthemen laut MEDLINE: Blood Pressure, Stroke, Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Brazilian Ministry of Health via the PROADI-SUS (Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde) program.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
In high cardiovascular risk populations without prior stroke, intensive blood pressure (BP) lowering confers greater reductions in cardiovascular events than standard targets. However, optimal BP targets in patients with ischaemic stroke (IS) or TIA remain uncertain. The primary objective of the OPTIMAL-STROKE trial is to assess whether an intensive systolic BP (SBP) target (SBP < 120 mmHg) reduces major cardiovascular events in patients with previous IS or TIA compared to a standard SBP target (SBP < 140 mmHg). Study design OPTIMAL-STROKE is a multicentre, randomised, controlled, open-label clinical trial with blinded and independent assessment of clinical outcomes and intention-to-treat primary analysis. Patients with a history of IS or TIA and high BP (SBP of 130–180 mmHg), clinically stable for at least 48 h prior to trial inclusion, are centrally randomised with concealed allocation in a 1:1 ratio to either an intensive BP control strategy targeting a SBP < 120 mmHg or a standard control strategy targeting a SBP < 140 mmHg. A total of 495 primary outcome events, 4368 patients enrolled. Study endpoints The primary outcome is the first occurrence of a composite outcome of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or hospitalisation for heart failure). Summary OPTIMAL-STROKE will be the first adequately powered trial of intensive BP control in the prevention of major cardiovascular events in patients with a history of IS or TIA.
Trial registration
The trial is registered at ClinicalTrials.gov (NCT04036409).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701, Morumbi, São Paulo, SP CEP 05652-900, Brazil.
- Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, SP CEP 04023-062, Brazil.
- Nexus Research Partners, 30 Eastcheap, London EC3M 1HD, United Kingdom.
- Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2350, Santa Cecília, Porto Alegre, RS CEP 90035-903, Brazil.
- Hospital Moinhos de Vento, Rua Ramiro Barcelos, 910, Bairro Moinhos de Vento, Porto Alegre, RS CEP 90560-032, Brazil.
- Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Monte Alegre, Ribeirão Preto, SP CEP 14049-900, Brazil.
ORCID-Profile: Gisele S Silva, M J Machline-Carrion, Karla Santo, João B Clares de Andrade, Eduardo Martins, Patrícia Guimarães, Frederico Monfardini, Josué Nieri, Silvia R L Assis, Sheila Cristina O Martins, Octávio M Pontes Neto, Audes D M Feitosa, Carla H C Moro, Sandra C Fuchs, Rubens Gagliardi, Odilson Silvestre, Ricardo Pereira Silva, Murillo Antunes, Maramélia M Alves, Cesar Minelli, Lilia N Maia, Luiz A Bortolotto, Marcio G Sousa, Luciano F Drager, Rodrigo Bazan, José F Vilela-Martin, Jamary Oliveira-Filho, Viviane Zetola, Wagner Avelar, Leonardo A Carbonera, Gabriel P Braga, Adriana B Conforto, Caio A M Tavares, Fabrício O Lima, Gladys L Martins, Letícia Costa Rebello, Anthony Rodgers, Paul K Whelton, Flavio D Fuchs, Otavio Berwanger
Förderung
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
- Brazilian Ministry of Health via the PROADI-SUS (Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde) program
Zitieren
APA
Silva, G. S., Machline-Carrion, M. J., Santo, K., Clares de Andrade, J. B., Martins, E., Guimarães, P., Monfardini, F., Nieri, J., Assis, S. R. L., Martins, S. C. O., Pontes Neto, O. M., Feitosa, A. D. M., Moro, C. H. C., Fuchs, S. C., Gagliardi, R., Silvestre, O., Pereira Silva, R., Antunes, M., Alves, M. M., …, & Berwanger, O. (2026). Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial. European Stroke Journal, 11(10). https://doi.org/10.1093/esj/aakag118
Vancouver
Silva GS, Machline-Carrion MJ, Santo K, Clares de Andrade JB, Martins E, Guimarães P, et al. Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial. European Stroke Journal. 2026;11(10). doi:10.1093/esj/aakag118
BibTeX
@article{Silva2026,
author = {Silva, Gisele S and Machline-Carrion, M J and Santo, Karla and Clares de Andrade, João B and Martins, Eduardo and Guimarães, Patrícia and Monfardini, Frederico and Nieri, Josué and Assis, Silvia R L and Martins, Sheila Cristina O and Pontes Neto, Octávio M and Feitosa, Audes D M and Moro, Carla H C and Fuchs, Sandra C and Gagliardi, Rubens and Silvestre, Odilson and Pereira Silva, Ricardo and Antunes, Murillo and Alves, Maramélia M and Minelli, Cesar and Maia, Lilia N and Bortolotto, Luiz A and Sousa, Marcio G and Drager, Luciano F and Bazan, Rodrigo and Vilela-Martin, José F and Oliveira-Filho, Jamary and Zetola, Viviane and Avelar, Wagner and Carbonera, Leonardo A and Braga, Gabriel P and Conforto, Adriana B and Tavares, Caio A M and Lima, Fabrício O and Martins, Gladys L and Rebello, Letícia Costa and Rodgers, Anthony and Whelton, Paul K and Fuchs, Flavio D and Berwanger, Otavio},
title = {Intensive blood-pressure control for the prevention of major cardiovascular events in stroke patients: rationale and design of the OPTIMAL-STROKE trial},
journal = {European Stroke Journal},
year = {2026},
volume = {11},
number = {10},
doi = {10.1093/esj/aakag118}
}
EUVIMED